title: A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones.
abstract: The objective of this multicenter, randomized, controlled, parallel group trial was to evaluate the efficacy of levofloxacin 250 mg oral, once daily (LVFX), placebo one tablet oral once daily (Placebo [P] group) and ciprofloxacin (CPFX) 500 mg oral, twice daily (single blind), prophylaxis in preventing bacteriuria (> or = 10(3) CFU/ml) in post-surgical catheterized patients. In the modified intention-to-treat (M-ITT) population of the 82 enrolled patients, negative bacteriuria was observed in 92% of LVFX group, in 80% of P group and in 100% of CPFX group while in the per-protocol (PP) population figures were: 100%, 86.4% and 100% respectively. Only one symptomatic urinary tract infection and one surgical wound infection were observed in the P group. Both drugs were well tolerated, showing a safety profile comparable to placebo. The high frequency of negative bacteriuria in the placebo group sounds encouraging as it underlines that the adoption of closed urinary drainage system catheters in hospital setting may reduce the frequency of hospital-acquired infections.
authors.affiliation: Department of Infectious Diseases, Second University of Naples, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Esposito
authors.forename: S
authors.initials: S
authors.lastname: Noviello
authors.forename: S
authors.initials: S
authors.lastname: Leone
authors.forename: A
authors.initials: A
authors.lastname: Marvaso
authors.forename: L
authors.initials: L
authors.lastname: Drago
authors.forename: F
authors.initials: F
authors.lastname: Marchetti
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000009:adverse effects / Q000379:methods*; D001437:Bacteriuria / Q000382:microbiology / Q000517:prevention & control; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D013293:Enterococcus faecalis / Q000302:isolation & purification; D004926:Escherichia coli / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000453:epidemiology; D005260:Female; D024841:Fluoroquinolones / Q000009:adverse effects / Q000627:therapeutic use*; D016908:Gram-Positive Bacterial Infections / Q000453:epidemiology; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010865:Pilot Projects; D010919:Placebos; D011776:Pyuria / Q000453:epidemiology; D016037:Single-Blind Method; D016896:Treatment Outcome; D014546:Urinary Catheterization / Q000009:adverse effects*; D014552:Urinary Tract Infections / Q000517:prevention & control*
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D010919:Placebos; D002939:Ciprofloxacin; D064704:Levofloxacin; D015242:Ofloxacin